Real Time Touch

new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)

Real Time Touch

Filing Names

Sanofi Pasteur
Sanofi Pasteur Sa
Sanofi Pasteur Biologics Llc
Sanofi Pasteur Limited
Sanofi Pasteur Biologics Co
Sanofi Pasteur Inc
Sanofi Pasteur Vaxdesign Corporation
Sanofi Pasteur Ltd
Sanofi Pasteur S a
Sanofi Pasteur Limited sanofi Pasteur Limitee
Sanofi Pasteur Vaxdesign Corp
Sanofi Pasteur_20100121

Sanofi Pasteur patents

Recent patent applications related to Sanofi Pasteur. Sanofi Pasteur is listed as an Agent/Assignee. Note: Sanofi Pasteur may have other listings under different names/spellings. We're not affiliated with Sanofi Pasteur, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "S" | Sanofi Pasteur-related inventors

Novel immunogenic formulations comprising linear or branched polyacrylic acid polymer adjuvants

The present invention provides for novel immunological and vaccine formulations comprising a newly applied non-crosslinked polyacrylic acid polymer adjuvant. The adjuvants may be combined with a wide variety of immunogens to produce vaccines that are safe and effective when administered to a wide range of target animals. The immunogens may... Sanofi Pasteur

Vaccine compositions against dengue virus diseases

The present invention relates to vaccine compositions that are useful in a method of protecting a human subject against dengue disease.... Sanofi Pasteur

Method for producing haemophilus influenzae type b antigens

The invention concerns a method for producing, on an industrial scale, capsular polysaccharide of Haemophilus influenzae type b (PRP) intended for vaccine purposes, according to which a strain of Haemophilus influenzae type b (Hib) is cultured in a culture medium, the culture supernatant is harvested and treated in order to... Sanofi Pasteur

Meningococcal vaccine based on lipooligosaccharide (los) originating from modified neisseria meningitidis strains of immunotype l6

The invention especially relates to multivalent vaccine compositions that can treat or prevent at least 60, preferably 75% of infections caused by Neisseria meningitidis especially of serogroup B. To this end, the invention in particular provides a lipooligosaccharide (LQS) of N. meningitidis in particular constituted by a lipid A, an... Sanofi Pasteur

Detoxification lipopolysaccharide (lps) or lipid a of gram-negative bacteria

The invention relates to a method of detoxifying a lipopolysaccharide (LPS) or a lipid A from a Gram-negative bacterium, which comprises mixing the LPS or the lipid A with a cationic lipid so as to form a complex in which the LPS or the lipid A is associated with the... Sanofi Pasteur

Liquid feeding device for the generation of droplets

The present invention provides, inter alia, for a liquid feeding device for the generation of droplets, in particular for the use in a process line for the production of freeze-dried particles, with a droplet ejection section for ejecting liquid droplets in an ejection direction, the droplet ejection section comprising at... Sanofi Pasteur

Immunogenic compositions

This disclosure relates to immunogenic compositions comprising an isolated immunogenic S. pneumoniae PcpA polypeptide, at least one additional antigen (such as for example, an isolated immunogenic S. pneumoniae polypeptide selected from the group consisting of the polyhistidine triad family of proteins (e.g., PhtD), and at least one isolated detoxified pneumolysin... Sanofi Pasteur

Assay for diagnosing streptococcus pneumoniae

Assays for detecting anti-streptococcal antibodies in biological samples using one or more streptococcal antigens are described herein. Various combinations of antigens may be used in the assays. For example, one or more of Ply, PhtD, PhtE, LytB and PcpA may be utilized. Additional streptococcal antigens may also be used. The... Sanofi Pasteur

Immunological compositions

The disclosure relates to immunological compositions for vaccinating human beings against infection by the Human Immunodeficiency Virus (HIV).... Sanofi Pasteur

Toxoid, compositions and related methods

The disclosure relates to generally to the field of toxin inactivation. More specifically, it relates to clostridial toxins, methods of inactivating these toxins and compositions (e.g., vaccines) comprising toxoids (e.g., produced by these methods). Provided are methods of producing a C. difficile toxoid comprising inactivating a C. difficile toxin with... Sanofi Pasteur

Synergistic co-administration of computationally optimized broadly reactive antigens for h1n1 influenza

The present invention provides co-administration (for example, immunogenic cocktail compositions and/or prime-boost regimens) of computationally optimized H1N1 influenza hemagglutinin (HA) polypeptides. Co-administration of the optimized H1N1 influenza hemagglutinin (HA) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (e.g., a broad reactive immune response) to diverse... Sanofi Pasteur

Compositions and methods for immunizing against c. difficile

This disclosure relates to methods for eliciting an immune response against C. difficile toxin A and toxin B in an adult human subject. The subject may be at risk for a primary symptomatic C. difficile infection. In some embodiments, a method is for eliciting an immune response against C. difficile... Sanofi Pasteur

Expression and conformational analysis of engineered influenza hemagglutinin

The present invention provides, among other things, compositions and methods for analyzing the expression and conformation of engineered influenza hemagglutinin In particular, the present invention provides methods of screening in silico designed HA antigens using neutralizing antibody panels specific to conserved epitopes. In some embodiments, the HAs are down selected... Sanofi Pasteur

Pharmaceutical compositions containing clostridium difficile toxoids a and b

This invention relates to compositions including Clostridium difficile toxins and/or toxoids and corresponding methods. The compositions of the invention include one or more excipients that increase stability and/or decrease aggregation of the toxins.... Sanofi Pasteur

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009


This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. is not affiliated or associated with Sanofi Pasteur in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Sanofi Pasteur with additional patents listed. Browse our Agent directory for other possible listings. Page by